

28 September 2026

US\$806,000 Migration Contract Secured with University of Michigan Health-Sparrow

- US\$806,000 total contract value for a project with University of Michigan Health-Sparrow for the migration of approximately 10.6 million radiology and cardiology imaging studies.
- The project incorporates Ensign standardisation across the historical imaging archive, demonstrating the value of combining Enlitic's migration and data standardisation capabilities at significant scale.
- University of Michigan Health-Sparrow will become Enlitic's first customer to utilise its Sectra integration, marking an important expansion of Ensign into Sectra-based imaging environments.
- The contract builds on Enlitic's growing commercial momentum in the US, following significant CY2026 engagements with leading healthcare providers including Penn Medicine, St. Jude Children's Research Hospital and Parkland Health.
- Enlitic's low-risk Class I regulatory classification provides a streamlined pathway to commercial deployment across key global markets, with its US product exempt from FDA premarket submission and approval.

Please view the announcement here on our website: <https://enlitic.com/link/P7Nj5r>

Enlitic, Inc. (ASX: ENL) ("Enlitic" or the "Company") is pleased to confirm it has secured a US\$806,000 (A\$1.15 million¹) total contract value with University of Michigan Health-Sparrow for the migration of approximately 10.6 million radiology and cardiology imaging studies. The project is expected to be completed within 12 months. The contract marks Enlitic's sixth imaging data migration project with University of Michigan Health, extending its established relationship with the health system to UM Health-Sparrow. Importantly, the project incorporates Ensign standardisation across the historical imaging archive, embedding Enlitic's technology within a large-scale healthcare data migration.

The project also marks Enlitic's first active integration with a Sectra customer. The integration enables the results of Ensign's standardisation and associated reporting to be incorporated into the University's Sectra-based imaging environment, marking the first customer application of Ensign alongside one of the world's leading enterprise imaging platforms.

¹ US\$806k converted based on a USD:AUD exchange rate of 0.7008.

The engagement is another significant example of a leading US healthcare provider using Ensign to standardise imaging data as part of a major migration. The combination of Enlitic's established migration expertise and Ensign creates a natural pathway to introduce Enlitic's technology into large and complex healthcare environments as customers modernise their imaging infrastructure.

The contract builds on Enlitic's growing commercial momentum in the US, following significant CY2026 engagements with Penn Medicine, St. Jude Children's Research Hospital and Parkland Health. Migrations remain an important revenue channel for Enlitic and provide potential opportunities to expand the use of Ensign across large healthcare organisations.

Enlitic's technology meets applicable regulatory requirements across key markets, including the US, UK, EU, NZ and Australia. Its Class I regulatory classification reflects the low-risk nature of the technology and provides a streamlined regulatory pathway, enabling Enlitic to commercially deploy its technology across these key markets.

Additionally, in the US our product is classified a low-risk Class 1 device, exempt from premarket submission and approval.

Michael Sistenich, Managing Director of Enlitic, said: "This contract with another leading US healthcare provider demonstrates the commercial momentum we are building and the increasing opportunity to combine our migration and Ensign capabilities. Importantly, it also marks our first active integration with a Sectra customer. With approximately 10.6 million studies in scope, this is a significant real-world deployment of our technology at scale."

This announcement was authorised for release by the Board of Enlitic, Inc.

- ENDS -

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, Xray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.

Forward-looking statements

Certain statements made during or in connection with this announcement contain or comprise certain forward-looking statements regarding the Company, its projected cash flow, financial performance, its customer contracts and customer pipeline and product development. Although the

Company believes that the expectations reflected in such forward-looking statements are reasonable, such expectations are only predictions and are subject to inherent risks and uncertainties which could cause actual values, results, performance or achievements to differ materially from those expressed, implied or projected in any forward-looking statements and no assurance can be given that such expectations will prove to have been correct.

Accordingly, results could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic and market conditions, delays or changes in product development and realisation of customer pipeline, changes in demand, success of business and operating initiatives, changes in the regulatory environment and other government actions, fluctuations in exchange rates and business and operational risk management.

To the maximum extent permitted by law, each of the Company, its officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in these forward-looking statements and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in forward-looking statements or any error or omission. The Company undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events other than required by the applicable laws, including the ASX Listing Rules. Accordingly, you should not place undue reliance on any forward-looking statement.

Read more at enlitic.com

About University of Michigan Health-Sparrow

University of Michigan Health-Sparrow is the project site for the migration engagement covered by this announcement and is part of the University of Michigan health system.

About Sectra

Sectra is a publicly traded Swedish medical technology company. With over 30 years of innovation, Sectra manages 170 million annual imaging exams and is a leading provider to health systems worldwide. Imaging modules for radiology, cardiology, pathology, orthopaedics, ophthalmology, and genomics, as well as a robust VNA and an optimized workflow engine, form an integrated enterprise diagnostic solution designed to support both human driven and AI driven clinical workflows. In 2026, Sectra won 7 Best in KLAS awards for the highest customer satisfaction. Visit <https://sectra.com/>

Further information:

Ben Jarvis
Six Degrees Investor Relations
Ph: 0413 150 448
Ben.jarvis@sdir.com.au